Savara Inc Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities
Savara Inc (SVRA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities of $2.40 million as of 2017-04-27, per its 10-Q filed 2018-11-07.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Liability Assumed, Liability › Business Combination, Recognized Liability Assumed, Liability, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities · last filed 2018-11-07
- 2017-04-27: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities $2.40M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities |
|---|---|
| 2017-04-27 | $2.40M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |